Floatz logo

TACROLIMUS

Complete Atypical DiGeorge Anomaly

Sumitomo Pharma Switzerland GmbHSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Complete Atypical DiGeorge Anomaly cohort.

Asset / SponsorPhaseRating
DACLIZUMAB
Sumitomo Pharma Switzerland GmbH
Phase 1/2CCC
ALLOGENEIC THYMOCYTE DEPLETED PROCESSED THYMUS TISSUE SLICES
Sumitomo Pharma Switzerland GmbH
Phase 1/2CCC
CYCLOSPORIN A
Sumitomo Pharma Switzerland GmbH
Phase 1/2CCC
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Sumitomo Pharma Switzerland GmbH
Phase 1/2CCC
Rabbit Anti-Thymocyte Globulin
Sumitomo Pharma Switzerland GmbH
Phase 1/2CCC
Monomethyl Fumarate
Sumitomo Pharma Switzerland GmbH
Phase 1/2CCC

Same molecule, other indications

TACROLIMUS is also rated in:

disease related to transplantationDormant
BBB
Indicative ·
79 / 100
View asset →
disease related to solid organ transplantationDormant
BBB
Indicative ·
76 / 100
View asset →
beta-thalassemia majorDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →